Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
左乙拉西坦治疗不同年龄癫痫患儿的长程有效性及耐受性观察:210例报道
by
冯雪菲 肖农
in
不良反应
/ 左乙拉西坦
/ 治疗结果
/ 癫痫
2014
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Do you wish to request the book?
左乙拉西坦治疗不同年龄癫痫患儿的长程有效性及耐受性观察:210例报道
by
冯雪菲 肖农
in
不良反应
/ 左乙拉西坦
/ 治疗结果
/ 癫痫
2014
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
左乙拉西坦治疗不同年龄癫痫患儿的长程有效性及耐受性观察:210例报道
2014
Request Book From Autostore
and Choose the Collection Method
Overview
目的探讨左乙拉西坦(LEV)单药或联合治疗不同年龄癫痫患儿的临床疗效及其安全性。方法纳入2006年7月-2007年6月西南地区210例门诊癫痫患儿,分为婴儿组(n=58)、幼儿组(n=46)、学龄前组(n=60)、学龄组(n=40)、青春期组(n=6),给予LEV单药或联合治疗,LEV起始剂量即为治疗剂量:儿童10mg/(kg.d),分2次服用,逐渐加量,3-4周达目标剂量,最大剂量〈60mg/(kg.d)。对入组后服药的各组患儿进行4年随访,根据发作频率自身对照评价疗效,观察不良反应。结果治疗前后自身对照可见,各组患儿治疗后的发作频率均较基线水平明显减少(P〈0.01);治疗后组间比较可见,各组服药后发作频率减少的差异无统计学意义(-P〉0.05)。婴儿组、幼儿组、学龄前组、学龄组患儿的有效率分别为70.o%(40/s8)、76.1%(35/46)、58.3%(3s/60)和82.5%(33/40),完全缓解率分别为41.8%(26/58)、58.7%(27/46)、41.796(25/60)和67.5%(27/40)。患儿主要不良反应为睡眠增多、烦躁不安、倦怠乏力、头痛、行为异常、学习困难、认知减退、纳差等。各组不良反应发生率为:婴儿组39.7%(23例),幼儿组54.3%(25例)。学龄前组61.7%(37例),学龄组52.5%(21例)。不同年龄组患儿不良反应发生的种类及比例不同。结论LEV可使各年龄组癫痫患儿发作频率明显降低,学龄组患儿有效性更高;LEV不良反应持续时间较短,发生率低,且在婴儿时期发生率最低。
MBRLCatalogueRelatedBooks
Related Items
Related Items
We currently cannot retrieve any items related to this title. Kindly check back at a later time.
This website uses cookies to ensure you get the best experience on our website.